

DFIN CASE STUDY

How we helped a pharma company capitalize on IPO market conditions and timing

DFIN



PMVPharma

PMV Pharma is a precision oncology company pioneering small molecule, tumor-agnostic therapies.



Founded in 2013

Now headquartered in
Cranbury, New Jersey



IPO Seven Years Later

Raised in \$234M
at \$18 per share



FDA Fast Track 3 Months after IPO

Granted to lead product
candidate

CHALLENGE

Executing a successful IPO, followed by a 10-Q and 10-K, with a very small staff

PMV Pharma decided to take their private company public with a rapid initial public offering (IPO). They set an aggressive deadline of three months to close before the IPO window closed for the year.

This gave a newly hired executive little time to draft and file Form S-1, followed soon after by Forms 10-Q and 10-K.



SOLUTION

DFIN financial reporting software, VDRs & expert support helped PMV Pharma go public

PMV Pharma is a small company with little staff, but they successfully planned, executed, and closed their IPO in only four months!

Venue virtual data room software made it possible for a team of advisors, lawyers, accountants, and stakeholders to gather relevant documents. ActiveDisclosure financial reporting software allowed them to quickly move to meeting post-IPO SEC reporting and auditing requirements. DFIN experts and project managers supported and streamlined the entire process.


DFIN is the global leader for IPO services – and we have the numbers to prove it. Over the last six years, DFIN:

Filed
700+
Traditional IPOs

Partnered on
70%
Traditional IPOs valued at >\$100M

Serviced
350+
SPACs

In our opinion, the unaudited interim condensed consolidated financial statements contain all adjustments (consisting of only normal recurring adjustments) necessary to present fairly. ¹



November 1...

September 2...

REDACT AND SAVE

Top Documents

1.1 - te...

2.1 - 04...

12.2 - 3...

15 - 3.8...

8.4 - Re...

8.5 - Sa...

33.4 - be...

04 - Re...

“If we hadn’t had ActiveDisclosure in place, however, I’m not sure how we would have survived at all.


We had a third-quarter 10-Q requirement very soon after IPO, and without AD, we would have had to work either through our attorneys or with a paper proofing process that would have been extremely inefficient.”

J.D. KERN
VP & Controller
PMV Pharma



Accelerate the IPO process

An IPO can be a long, demanding, and complicated process that will have long-term implications for your company. Our IPO solutions and experts help you successfully navigate the intricacies and prepare for life as a public company.



Preparation
Advice for planning ahead



Pre-Filing
An overview of the IPO process



Initial submission of S-1
Recommendations for SEC review



SEC review
Guidance for building your company's finance organization



Roadshow
Suggestions on how to successfully market, price and distribute your IPO



Pricing/Trading
Tips for navigating underwriting





Get in touch

DFINsolutions.com

NORTH AMERICA: +1 800 823 5304

APAC: +852 2522 3803

EMEA: +44 203 047 6100

LATAM: +55 11 3031 6327